Educational resources

Guidelines in Practice has developed a range of educational resources—including animations, formulary decision guides, implementation checklists, supplements, and webinars—to support you with your learning and implementation of best practice

Guidelines in Practice webinars provide a 1-hour update from expert speakers on the latest evidence and guidance. Available live and on-demand

Website-banner3x2

Exploring a Cardiovascular approach to patients with Type 2 Diabetes with a focus on current guidance

2019-11-29T09:10:00+00:00Commissioned by Boehringer Ingelheim Limited and Lilly Diabetes Alliance

This webinar has been commissioned by Boehringer Ingelheim Limited and Lilly Diabetes Alliance and organised in partnership with Guidelines in Practice. See below for full disclaimer.

Screen Shot 2019-10-22 at 11.25.04

Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)

2019-10-22T10:22:00+01:00Commissioned by Takeda UK Ltd

This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.

Header image 3 2 small

Nailing your onychomycosis management

2019-05-16T06:45:00+01:00Commissioned by Bayer Plc

Contains promotional content

Website-banner

Introduction and implementation of the NICE asthma guidelines

2019-04-01T12:45:00+01:00Commissioned by Teva UK Limited

This webinar has been commissioned by Teva UK Limited and organised in partnership with Guidelines in Practice. See bottom of page for full disclaimer.

Guidelines in Practice snapshot animations provide a quick overview of best-practice topics related to clinical guidance and medicines—update your knowledge in 10 minutes

Management of hyperglycaemia in T2D (animation)

Management of hyperglycaemia in type 2 diabetes, 2018: ADA/EASD consensus report

2019-04-09T09:38:00+01:00Commissioned by Napp Pharmaceuticals Limited

Watch this short animation, commissioned by Napp Pharmaceuticals Limited, to find out about the third joint consensus report on the management of hyperglycaemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Guidelines in Practice implementation checklists collate the key recommendations from clinical guidance to help you easily apply them to your practice

If you want to update your knowledge on specific drugs, or need to collate information to support your formulary decisions, read our Guidelines in Practice formulary decision guides

Formulary decision guide on Trajenta

Trajenta® (linagliptin) 5 mg film-coated tablets

2019-12-04T04:58:00+00:00Promotional material from Boehringer Ingelheim Limited and Lilly Diabetes Alliance

Information intended for healthcare professionals only.

20190814 Ozempic FDG v11 digital thumbnail

Formulary decision guide: Ozempic®▼ (semaglutide)

2019-08-19T13:22:00+01:00Commissioned by Novo Nordisk Limited

Information intended for healthcare professionals only. This formulary decision guide was developed from content supplied by Novo Nordisk in a format developed by Guidelines in Practice. It has been reviewed by Novo Nordisk, who commissioned the development of the formulary decision guide.

Latest supplements

Guidelines in Practice supplements provide expert opinion articles on a range of clinical and commissioning areas. Our supplement range includes the following types: Product Review; Guidance Update; Local Implementation.

Stable angina supplement image

Delivering savings by improving the management of patients with chronic coronary syndrome in the AMU setting: a case study

2019-11-07T14:40:00+00:00Commissioned by A. Menarini Farmaceutica Internazionale SRL

Alan Begg PAD video

Secondary event prevention and risk stratification in patients with symptomatic peripheral arterial disease (PAD)

2019-10-11T13:33:00+01:00Commissioned by Bayer Plc

Information intended for healthcare professionals only. The development of this Guidelines in Practice video has been commissioned by Bayer plc. Please see the bottom of the page for full disclaimer.